HONG KONG – Research in T-cell therapy has been gaining momentum, with biotech giants like Gilead Sciences Inc. keenly investing in the area. Meanwhile, Lion TCR Pte. Ltd., a smaller company based in Singapore, is also seeing progress with its T-cell therapy treatment for hepatocellular carcinoma (HCC).